MNG35
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.356
- KRAS_SIGNALING_DN+0.319
- SPERMATOGENESIS+0.308
- MYOGENESIS+0.221
- WNT_BETA_CATENIN_SIGNALING+0.195
- PANCREAS_BETA_CELLS+0.194
- ANGIOGENESIS+0.144
- COAGULATION+0.118
- APICAL_SURFACE+0.101
- BILE_ACID_METABOLISM+0.101
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.605
- IL6_JAK_STAT3_SIGNALING-0.504
- INTERFERON_ALPHA_RESPONSE-0.488
- UNFOLDED_PROTEIN_RESPONSE-0.479
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.471
- TNFA_SIGNALING_VIA_NFKB-0.454
- MYC_TARGETS_V1-0.445
- MYC_TARGETS_V2-0.443
- INTERFERON_GAMMA_RESPONSE-0.431
- ALLOGRAFT_REJECTION-0.428
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG189 | — | — | 0.890 |
| 2 | MNG355 | — | — | 0.883 |
| 3 | TCGA-CN-A49A-01A-11R-A24H-07 | — | — | 0.881 |
| 4 | SRR6013476 | — | cohortSQ1 | 0.878 |
| 5 | SRR1362417 | GTEX | — | 0.876 |
| 6 | BS_YMAJC22S | low-grade glioma | — | 0.873 |
| 7 | BS_CZ82ANWP | DNET | — | 0.868 |
| 8 | MDT-AP-3189 | Med | Medulloblastoma | 0.864 |
| 9 | 82982 | EPN | Supratentorial EPN | 0.864 |
| 10 | MBCProject_0589_T1A_RNA | — | A | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.356 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.319 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.308 | Inavolisib | — uncovered |
| MYOGENESIS | 0.221 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.195 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.194 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.144 | Remibrutinib | — uncovered |
| COAGULATION | 0.118 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.101 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.101 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.073 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.053 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.010 | Inavolisib | — uncovered |